Replies to post #260812 on Anavex Life Sciences Corp (AVXL)

[rayovacAAA]

INCORRECT. NO WHERE IN THE LINKED ARTICLE DOES IT SAY:

The Week Ahead In Biotech:

Anavex Life Sciences Corp
AVXL
: top-line results from the Phase 2 study of ANAVEX 2-73 in Parkinson's disease dementia Phase 2 trial

ACTUAL STATEMENT IN LINKED ARTICLE:

https://www.benzinga.com/general/biotech/20/07/16778963/the-week-ahead-in-biotech-spotlight-on-gw-pharma-ultragenyx-fda-decisions-pfizer-earnings

The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings

ACTUAL AVXL CONTENT CONTAINED IN LINKED ARTICLE:

https://www.benzinga.com/general/biotech/20/07/16778963/the-week-ahead-in-biotech-spotlight-on-gw-pharma-ultragenyx-fda-decisions-pfizer-earnings

Pending mid-2020 Releases:

Spectrum Pharmaceuticals, Inc. SPPI 4.28: top-line results from Cohort 2 of the ZENITH20 trial evaluating poziotinib in previously treated HER2 non-small cell lung cancer patients

Intra-Cellular Therapies Inc ITCI 0.23%: top-line results from a Phase 3 study evaluating lumateperone as adjunctive therapy in bipolar depression.

BioXcel Therapeutics Inc BTAI 1.35%: top-line results from a Phase 1/2b trial of BXCL501 for the acute treatment of agitation associated with geriatric dementia.

Alnylam Pharmaceuticals, Inc. ALNY 0.98%: top-line results from the ILLUMINATE-B Phase 3 study of lumasiran in primary hyperoxaluria type 1 patients less than six years of age with preserved renal function.

Karuna Therapeutics Inc KRTX 6.86%: data from Phase 1b clinical trial of KarXT in experimentally induced pain

Akari Therapeutics PLC AKTX 2.5%: interim update on the Part B placebo-controlled efficacy arm of the study of nomacopan eye drops in atopic keratoconjunctivitis

Seres Therapeutics Inc MCRB 7.24%: Data from SER-109 Phase 3 study in recurrent C. difficile infection

Mesoblast MESO 1.38%: data from a Phase 3 randomized controlled trial of Revascor for advanced heart failure

Akebia Therapeutics Inc (NASDAQ: AKBA: ) top-line data from the global Phase 3 studies evaluating the safety and efficacy of vadadustat in adult patients not on dialysis with anemia due to chronic kidney disease

Anavex Life Sciences Corp AVXL 1.12%: top-line results from the Phase 2 study of ANAVEX 2-73 in Parkinson's disease dementia Phase 2 trial

BIOLINERX LTD/S ADR BLRX 1.44%: Progression-free survival and overall survival data from the triple combination arm of the COMBAT/KEYNOTE-202 Phase 2a study of BL-8040 in combination with Merck & Co., Inc.'s
MRK 1.2%
Keytruda in advanced second-line pancreatic cancer

Arcus Biosciences Inc RCUS 3.95%: preliminary data from Phase 1b expansion trials involving combinations with AB928 in multiple tumor types and settings

Homology Medicines Inc FIXX 3.46% : additional data from Phase 1/2 pheNIX gene therapy trial for phenylketonuria

Vaxart Inc VXRT 11.26%: data from universal Influenza vaccine collaboration with Johnson & Johnson's

JNJ 1.02% Janssen unit

Albireo Pharma Inc ALBO 3.85%: top-line results from the Phase 3 PEDFIC 1 trial that is evaluating Odevixibat in progressive familial intrahepatic cholestasis; top-line data from the Phase 3 trial of elobixibat in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease

resTORbio, Inc. TORC 2.03%: data from the four completed cohorts of the Phase 1b/2a trial of RTB101 in combination with sirolimus in Parkinson's disease

[sokol]

“Pending mid-2020 Releases:”. The article list 16 biotech companies with pending “mid-2020 Releases”. So, Anavex is one of the 16 biotech’s this article mentions with pending mid-2020 releases. Now that we are about exhausted in bludgeoning Anavex and Missling, let’s expend any left over anguish in lambasting these other 15 biotechs that also have not reported data.

https://www.benzinga.com/general/biotech/20/07/16778963/the-week-ahead-in-biotech-spotlight-on-gw-pharma-ultragenyx-fda-decisions-pfizer-earnings